

Safety, immunogenicity, and effectiveness of Lassa vaccines in pregnant persons: A protocol for a living systematic review and meta-analysis

Mabel Berrueta, Agustin Ciapponi, Jamile Ballivian, Agustina Mazzoni, Ariel Bardach, Juan Manuel Sambade, Martin Brizuela, Katharina Stegelmann, Edward Parker, Andy Stergachis, Xu Xiong, Flor Munoz, Pierre Buekens

Review methods were amended after registration. Please see the revision notes and previous versions for detail.

To enable PROSPERO to focus on COVID-19 submissions, this registration record has undergone basic automated checks for eligibility and is published exactly as submitted. PROSPERO has never provided peer review, and usual checking by the PROSPERO team does not endorse content. Therefore, automatically published records should be treated as any other PROSPERO registration. Further detail is provided [here](#).

Citation 1 change

Mabel Berrueta, Agustin Ciapponi, Jamile Ballivian, Agustina Mazzoni, Ariel Bardach, Juan Manuel Sambade, Martin Brizuela, Katharina Stegelmann, Edward Parker, Andy Stergachis, Xu Xiong, Flor Munoz, Pierre Buekens. Safety, immunogenicity, and effectiveness of Lassa vaccines in pregnant persons: A protocol for a living systematic review and meta-analysis. PROSPERO 2024 Available from <https://www.crd.york.ac.uk/PROSPERO/view/CRD42024554330>

REVIEW TITLE AND BASIC DETAILS

Review title 1 change

Safety, immunogenicity, and effectiveness of Lassa vaccines in pregnant persons: A protocol for a living systematic review and meta-analysis

Original language title

English

Review objectives

- 1) What is the safety profile of the vaccine platforms or components of Lassa candidates and licensed vaccines (antigen, construct, adjuvants, other components) in pregnant persons?
- 2) What is the safety profile of Lassa candidates and licensed vaccines administered during pregnancy regarding adverse maternal/pregnancy, perinatal, neonatal, and postpartum outcomes?
- 3) What are the safety profile and tolerability of Lassa candidates and licensed vaccines administered during pregnancy regarding other nonpregnancy-related adverse maternal outcomes?
- 4) How effective are Lassa candidate and licensed vaccines in preventing and protecting pregnant persons from the disease?
- 5) What is the immune response associated with Lassa candidates and licensed vaccines, and how long does it last in vaccinated pregnant persons?
- 6) Are there Lassa virus-specific immune responses with antibody transfer from vaccinated pregnant persons to their newborns (placenta and breastmilk)?

Secondary review questions

- 1) Are there differential safety effects of various Lassa vaccine platforms or components (antigen, vehicle, construct, adjuvants, other components) used by Lassa candidates and licensed vaccines in pregnant persons?
- 2) Are there differential safety, effectiveness, and efficacy effects of Lassa vaccine candidates and licensed platforms in pregnant persons?
- 3) Are there differential safety, effectiveness, and efficacy effects of vaccines by trimester of exposure, maternal risk status, and/or maternal age?
- 4) Are there differential safety, effectiveness, and efficacy effects of vaccines by country income level or region in pregnant persons?
- 5) What immune response is associated with Lassa candidates and licensed vaccines, and how long does it last pregnant persons?
- 6) What are the long-term effects of Lassa virus vaccination (efficacy, safety) in pregnant persons?

Keywords

Lassa virus, living systematic review, vaccine

SEARCHING AND SCREENING

Searches

We intend to update the searches of this living systematic review (LSR) regularly to incorporate new relevant reports as they are released.

An experienced librarian will search the Cochrane Library databases, MEDLINE, EMBASE, Latin American and Caribbean Health Sciences Literature (LILACS), Science Citation Index Expanded (SCI-EXPANDED), EPPI-Centre map of the current evidence on Lassa, WHO Database of publications on Lassa virus, Lassa-related Congresses and laboratory reports, guidelines published by national and international professional societies (e.g., ACOG, RCOG, FIGO), preprint servers (e.g., ArXiv, BiorXiv, medRxiv, search.bioPreprint), and Lassa research websites.

We will search all the above databases from January 2014 to the present. No language restrictions will be applied. The searches will be updated every two weeks to incorporate new relevant reports as they become available. Besides, we will hand-search the reference lists of the identified systematic reviews and include studies to identify relevant studies missed by our search strategy. Ongoing randomized controlled trials will be tracked in Clinicaltrial.gov and other trial registers (WHO, etc.).

Additional search strategy information can be found in the attached PDF document (link provided below).

Study design

Experimental, quasi-experimental, and observational (comparative and non-comparative) study designs, irrespective of publication status, publication year, and language. We will include randomized controlled trials (all Phases I-IV), non-randomized trials, controlled before-after studies, nationwide uncontrolled before-after studies, interrupted time series, controlled-interrupted time series, and adverse events/safety registries, real-world Phase IV studies, cohort studies, case-control, cross-sectional studies, and case series. Case reports for previously unknown or unexpected adverse events will be included. Preclinical studies will be included.

ELIGIBILITY CRITERIA

Condition or domain being studied

Lassa virus vaccines

Population

Pregnant persons and their infants

Animals

Intervention(s) or exposure(s)

- 1) Vaccine platforms or components present in Lassa candidate and licensed vaccines used in other vaccines in pregnant persons (antigen, vehicle, construct, adjuvants, other components)
- 2) Lassa vaccines in pregnant persons or animals regardless of the dose and schedule.

Comparator(s) or control(s)

Active or inactive comparators without interventions under study, usual care, or placebo. Non-comparative studies will be included; therefore, a control group will not be mandatory.

OUTCOMES TO BE ANALYSED

Main outcomes

1. Safety outcomes

a. Safety maternal outcomes: standardized case definitions developed for obstetric outcomes by the Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) of prioritized obstetric and neonatal outcomes based on the Brighton Collaboration will be used. Outcomes included:

Maternal death, Spontaneous abortion/miscarriage, Stillbirth, Preterm delivery, Maternal hemorrhage (antenatal/peripartum/postnatal), myocarditis/pericarditis -

b. Safety neonatal outcomes:

Low birth weight (LBW), Small for gestational age (SGA), Intra Uterine Growth Restriction (IUGR), Congenital anomalies, including microcephaly, Neonatal death, preterm birth, neonatal sepsis.

c. Serious adverse events (SAEs) and all-cause mortality related to vaccination (in vaccinated pregnant people and their newborns).

Death, Congenital anomalies, fetal/Infant events with potential for health consequences: IUGR, LBW, SGA, Neonatal sepsis

Maternal events with potential for health consequences: Encephalitis, Myocarditis, Pericarditis, Hypertension, Eclampsia, Preeclampsia, Anemia, AKI, Hepatitis, among others

d. Adverse events of Special Interest (AESI) post-vaccination in pregnant persons (not related to pregnancy)

The outcomes include (but not limited to): Sensorineural hearing loss in mother and infant, Maternal hemorrhage or thrombotic

2. Efficacy/effectiveness in the prevention of Lassa Fever infection according to the WHO suggested case definition

Measures of effect

Odds ratios (ORs), Risk ratios (RRs), Hazard ratios (HRs) with 95% confidence intervals (95% CIs) for dichotomous outcomes and Mean difference (MD) or Standardized MD (SMD) for continuous outcomes will be estimated. Regarding efficacy/effectiveness, we will report Vaccine efficacy (VE). We will also calculate proportions with 95% CIs for non-comparative studies.

Additional outcomes

3. Immunogenicity:

a. immune cellular and humoral responses and duration of immunity (titers of IgM, IgG, and combined; neutralizing antibodies in maternal serum at delivery and umbilical cord blood and cellular response markers).

- b. transplacental transfer ratios.
- c. magnitude and duration of antibody response

DATA COLLECTION PROCESS

Data extraction (selection and coding)

Selection

A pair of review authors will independently screen each title and abstract. Any potentially relevant full-text study reports/publications will be retrieved and reviewed independently by two authors, recording the reasons for the exclusion of the ineligible studies.

Disagreements will be resolved through discussion with the review team. This process will be performed using the COVIDENCE web-based software.

Data extraction and management:

Study data will be collected and stored using REDCap electronic data capture tools hosted and maintained by IECS. Each REDCap study ID will include a general form where the principal characteristics of the studies will be included, and outcome-specific forms will be generated to extract data to independently assess each endpoint reported in the studies for every outcome. The data extraction will be piloted on a sample of at least ten studies before its formal start-up. Pairs of review authors will independently extract data from included studies in a REDCap form and will resolve disagreements through a discussion with the review team. If needed, we will contact the study authors by e-mail to specify any missing data that may not be reported sufficiently in the publication. Funding source information will be sought for every study included in the LSR.

Data items to consider for extraction from included studies will include identification, items, methods, participants, group allocation, intervention, outcomes, risk of bias, and summary of results.

Risk of bias (quality) assessment

Risk of bias (quality) assessment

- 1) Randomized controlled trials: we will use the Cochrane risk of bias tool - version 2 (RoB2)
- 2) Non-randomized studies of interventions: we will use the ROBINS-I tool.
- 3) Controlled before-after studies: we will assess baseline measurement, characteristics for studies using the second site as control, blinded assessment of primary outcome(s), reliable primary outcome measure(s), follow-up of professionals (protection against exclusion bias), and follow-up of patients.
- 4) Uncontrolled before-after studies: we will use the same criteria as controlled before-after studies, with the exception of baseline measurement and characteristics for studies using the second site as control.
- 5) Interrupted time series: we will assess the risk of bias associated with the following seven domains: intervention independent of other changes, shape of intervention effect pre-specified, intervention unlikely to affect data collection, blinding of outcome assessors to

intervention allocation, incomplete outcome data, selective outcome reporting, and other sources of bias.

6) Controlled interrupted time series studies: we included three additional domains that assess design-specific threats to validity: imbalance of outcome measures at baseline, comparability of intervention and control group characteristics at baseline, and protection against contamination.

We will present GRADE certainty of evidence in the 'Summary of findings' tables for main outcomes.

PLANNED DATA SYNTHESIS

Strategy for data synthesis

If data are available and methodologically appropriate, we will undertake the aggregate meta-analyses for each comparison according to the Cochrane Handbook of Systematic Reviews of Interventions and use the pre-random-effects meta-analysis for the primary analysis. We will also perform proportion meta-analyses to summarize frequencies from one-sample studies.

We will use R statistical software to analyze the data. The main packages selected for data analyses will be Meta, Metafor, and Tidyverse. We will estimate hazard ratios (HRs), risk ratios (RRs), or odds ratios (ORs) with 95% CI for dichotomous outcomes and mean difference (MD) or standardized MD (SMD) for continuous outcomes. We will also estimate proportions with 95% CI for non-comparative studies. To report efficacy/effectiveness outcomes, we will transform other outcome measures into vaccine efficacy/effectiveness (VE) whenever possible by calculating the risk of disease among vaccinated and the comparative group and determining the percentage reduction in disease risk among vaccinated persons relative to the control group. We will use adjusted effect measures (e.g., by age, smoking status, parity, body mass index, etc.) over unadjusted estimates. We will investigate heterogeneity through subgroup analyses.

We will provide a frequently updated an online and interactive app to present available data and main findings.

Analysis of subgroups or subsets

Pre-specified subgroups by pregnancy trimester (first, second or third trimester), country income level (high or low- and middle-income country), region (based on the Institute for Health Metrics and Evaluation categorization), maternal age, maternal risk status (low or high), by individual Lassa vaccine and/or platform. Additional sensitivity analyses will be undertaken by excluding high-risk bias studies or using the fixed-effect model.

REVIEW AFFILIATION, FUNDING AND PEER REVIEW

Review team members

- Dr Mabel Berrueta, Instituto de Efectividad Clínica y Sanitaria

- Dr Agustin Ciapponi, Instituto de Efectividad Clínica y Sanitaria
- Dr Jamile Ballivian, Instituto de Efectividad Clínica y Sanitaria
- Dr Agustina Mazzoni, Instituto de Efectividad Clínica y Sanitaria
- Dr Ariel Bardach, Instituto de Efectividad Clínica y Sanitaria
- Dr Juan Manuel Sambade, Instituto de Efectividad Clínica y Sanitaria
- Dr Martin Brizuela, Instituto de Efectividad Clínica y Sanitaria
- Katharina Stegelmann, Instituto de Efectividad Clínica y Sanitaria
- Dr Edward Parker, The Vaccine Centre, London School of Hygiene & Tropical MedicineThe Vaccine Centre, London School of Hygiene & Tropical Medicine
- Dr Andy Stergachis, University of Washington, Schools of Pharmacy and Public Health
- Xu Xiong, Tulane University, School of Public Health and Tropical Medicine
- Dr Flor Munoz, Baylor College of Medicine. Houston
- Dr Pierre Buekens, Tulane University, School of Public Health and Tropical Medicine

Review affiliation

Instituto de Efectividad Clínica y Sanitaria

Funding source

SPEAC \u2013 2013 under Special Populations Work Group, and Vor CEPI

Named contact

Agustin Ciapponi. Dr. Emilio Ravignani 2024, C1414CPV CABA
aciapponi@iecs.org.ar

TIMELINE OF THE REVIEW

Review timeline

Start date: 04 June 2024. End date: 30 September 2024

Date of first submission to PROSPERO

11 June 2024

Date of registration in PROSPERO

21 June 2024

CURRENT REVIEW STAGE

Publication of review results

The intention is not to publish the review once completed.

Stage of the review at this submission

Review stage	Started	Completed
Pilot work		
Formal searching/study identification		
Screening search results against inclusion criteria		
Data extraction or receipt of IP		
Risk of bias/quality assessment		
Data synthesis		

Review status

The review is currently planned or ongoing.

ADDITIONAL INFORMATION

PROSPERO version history

- Version 1.2 published on 08 Aug 2024
- Version 1.1 published on 21 Jun 2024
- Version 1.0 published on 21 Jun 2024

Review conflict of interest

None known

Country

Argentina

Medical Subject Headings

Adjuvants, Immunologic; Female; Humans; Immunity; Immunoglobulins; Infant, Newborn; Lassa virus; Maternal Age; Meta-Analysis as Topic; Milk, Human; Placenta; Postpartum Period; Pregnancy; Systematic Reviews as Topic; Vaccination; Vaccines

Revision note 1 change

There was only a typo in the title

Disclaimer

The content of this record displays the information provided by the review team. PROSPERO does not peer review registration records or endorse their content.

PROSPERO accepts and posts the information provided in good faith; responsibility for record content rests with the review team. The owner of this record has affirmed that the information provided is truthful and that they understand that deliberate provision of inaccurate information may be construed as scientific misconduct.

PROSPERO does not accept any liability for the content provided in this record or for its use. Readers use the information provided in this record at their own risk.

Any enquiries about the record should be referred to the named review contact